BeOne Medicines (ONC) Income from Continuing Operations (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Income from Continuing Operations data on file, last reported at 227357000.0 in Q1 2026.

• On a quarterly basis, Income from Continuing Operations rose 17802.13% year-over-year to 227357000.0 in Q1 2026; TTM through Mar 2026 was 513020000.0, a 230.75% increase from a year earlier, with the FY2025 full-year figure at 286933000.0, up 144.5% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 227357000.0, up from 66502000.0 in the prior quarter.
• Over the last five years, Income from Continuing Operations for ONC reached as high as 227357000.0 in Q1 2026 and fell as low as 565726000.0 in Q2 2022.
• Historically, Income from Continuing Operations has averaged 177412882.35 across 5 years, with a median of 151881000.0 in 2024.
• Across the five-year window, Income from Continuing Operations slumped 754.48% in 2022 and soared 17802.13% in 2026, its largest moves.
• Year by year, Income from Continuing Operations stood at 445335000.0 in 2022, then increased by 17.47% to 367553000.0 in 2023, then jumped by 58.68% to 151881000.0 in 2024, then jumped by 143.79% to 66502000.0 in 2025, then surged by 241.88% to 227357000.0 in 2026.
• Per Business Quant data, the three most recent Income from Continuing Operations figures were 227357000.0 in Q1 2026, 66502000.0 in Q4 2025, and 124841000.0 in Q3 2025.